Back to news

Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study

Globe Newswire•19/11/2026•07:00 ET
0

Key Highlights

  • ➤Marker Therapeutics (MRKR) awarded $16.2 million non-dilutive CPRIT grant
  • ➤Funding will support MT-601’s planned Phase 2 APOLLO study
  • ➤Phase 1 data showed 66% objective and 50% complete response rates
  • ➤Responses lasted up to 24 months at August 2025 data cutoff
  • ➤CPRIT selected 12 projects from 207 applications, awarding $74.3 million

Expert Statements

Juan Vera, President and Chief Executive Officer of Marker Therapeutics

“Securing this $16.2 million award from CPRIT is an important milestone for Marker and further reinforces our confidence in the potential of MT-601 in CAR-relapsed lymphoma”

Juan Vera, President and Chief Executive Officer of Marker Therapeutics

“Following a highly competitive selection and review process, this award provides meaningful external recognition of our differentiated MAR-T cell approach and substantial non-dilutive funding to support our Phase 2 APOLLO study to translate our early clinical findings into a much-needed new treatment option for patients with limited therapeutic alternatives.”

Juan Vera, President and Chief Executive Officer of Marker Therapeutics

“We look forward to providing updated clinical results later this year and advancing MT-601 through its next stage of clinical development.”

Geoffrey Shouse, Principal Investigator at City of Hope National Medical Center

“Despite significant advances in the treatment of large B-cell lymphoma, patients who relapse following CAR-T therapy continue to face limited treatment options and poor clinical outcomes”

Geoffrey Shouse, Principal Investigator at City of Hope National Medical Center

“Through our experience with MT-601 in the Phase 1 APOLLO study, we have observed encouraging clinical activity and a favorable safety profile in heavily pretreated patients, including those who have progressed following multiple prior lines of therapy.”

Geoffrey Shouse, Principal Investigator at City of Hope National Medical Center

“We believe MT-601 represents a promising therapeutic approach and has the potential to meaningfully change the treatment landscape for patients with LBCL who relapse after CAR-T therapy.”

Kristen Doyle, Chief Executive Officer of CPRIT

“The awards funded reflect the extraordinary innovation taking place across Texas,”

Kristen Doyle, Chief Executive Officer of CPRIT

“These investments support researchers, clinicians, entrepreneurs, and community leaders who are helping shape the future of cancer care and bringing new hope to Texans and Texas families.”

Highly competitive grant award provides significant non-dilutive funding to support Phase 2 development of MT-601 in CAR-relapsed lymphoma

CPRIT award builds on encouraging Phase 1 clinical results, with additional patient data and updated response durability data expected later this year

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in